181 related articles for article (PubMed ID: 22143367)
21. Down-regulation of vasoactive intestinal peptide and altered expression of its receptors in rat diabetic cardiomyopathy.
Dvoráková MC; Pfeil U; Kuncová J; Svíglerová J; Galvis G; Krasteva G; König P; Grau V; Slavíková J; Kummer W
Cell Tissue Res; 2006 Mar; 323(3):383-93. PubMed ID: 16344947
[TBL] [Abstract][Full Text] [Related]
22. Alterations of vasoactive intestinal polypeptide receptors in allergic rhinitis.
Kim DH; Park IH; Cho JS; Lee YM; Choi H; Lee HM
Am J Rhinol Allergy; 2011; 25(1):e44-7. PubMed ID: 21711977
[TBL] [Abstract][Full Text] [Related]
23. [Analysis of enteral nervous system in children with drug resistant ulcerative colitis].
Kamińska B; Landowski P; Gonkowski S; Szlagatys-Sidorkiewicz A; Majewski M; Dobosz M; Ismail H; Korzon M
Med Wieku Rozwoj; 2007; 11(2 Pt 1):117-22. PubMed ID: 17625279
[TBL] [Abstract][Full Text] [Related]
24. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
25. The role of vasoactive intestinal peptide (VIP) in megakaryocyte proliferation.
Nam C; Case AJ; Hostager BS; O'Dorisio MS
J Mol Neurosci; 2009 Feb; 37(2):160-7. PubMed ID: 18663606
[TBL] [Abstract][Full Text] [Related]
26. Endogenous inhibition of hippocampal LTD and depotentiation by vasoactive intestinal peptide VPAC1 receptors.
Cunha-Reis D; Aidil-Carvalho Mde F; Ribeiro JA
Hippocampus; 2014 Nov; 24(11):1353-63. PubMed ID: 24935659
[TBL] [Abstract][Full Text] [Related]
27. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
28. Substance P and vasoactive intestinal polypeptide but not calcitonin gene-related peptide concentrations are reduced in patients with moderate and severe ulcerative colitis.
Renzi D; Mantellini P; Calabrò A; Panerai C; Amorosi A; Paladini I; Salvadori G; Garcea MR; Surrenti C
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):62-70. PubMed ID: 9615269
[TBL] [Abstract][Full Text] [Related]
29. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
30. VPAC1 overexpression is associated with poor differentiation in colon cancer.
Liu S; Zeng Y; Li Y; Guo W; Liu J; Ouyang N
Tumour Biol; 2014 Jul; 35(7):6397-404. PubMed ID: 24671823
[TBL] [Abstract][Full Text] [Related]
31. Location and function of VPAC1, VPAC2 and NPR-C receptors in VIP-induced vasodilation of porcine basilar arteries.
Grant S; Lutz EM; McPhaden AR; Wadsworth RM
J Cereb Blood Flow Metab; 2006 Jan; 26(1):58-67. PubMed ID: 15959462
[TBL] [Abstract][Full Text] [Related]
32. Differential expression of vasoactive intestinal peptide and its functional receptors in human osteoarthritic and rheumatoid synovial fibroblasts.
Juarranz Y; Gutiérrez-Cañas I; Santiago B; Carrión M; Pablos JL; Gomariz RP
Arthritis Rheum; 2008 Apr; 58(4):1086-95. PubMed ID: 18383383
[TBL] [Abstract][Full Text] [Related]
33. [effect of treatment from the lung and treatment from the intestine on vasoactive intestinal peptide contents of ulcerative colitis rats: a comparison study].
Yang X; Wang XY; Jing S; Yang S; Yan X; Sheng YH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2015 Feb; 35(2):222-7. PubMed ID: 25881470
[TBL] [Abstract][Full Text] [Related]
34. Immunocytochemical localization of vasoactive intestinal peptide and substance P in the colon from normal subjects and patients with inflammatory bowel disease.
Mazumdar S; Das KM
Am J Gastroenterol; 1992 Feb; 87(2):176-81. PubMed ID: 1370872
[TBL] [Abstract][Full Text] [Related]
35. Expression of mRNA for vasoactive intestinal peptide in normal human colon and during inflammation.
Schulte-Bockholt A; Fink JG; Meier DA; Otterson MF; Telford GL; Hopp K; Koch TR
Mol Cell Biochem; 1995 Jan; 142(1):1-7. PubMed ID: 7753037
[TBL] [Abstract][Full Text] [Related]
36. Suppression of tumorigenicity in neuroblastoma cells by upregulation of human vasoactive intestinal peptide receptor type 1.
Balster DA; O'Dorisio MS; Albers AR; Park SK; Qualman SJ
Regul Pept; 2002 Nov; 109(1-3):155-65. PubMed ID: 12409228
[TBL] [Abstract][Full Text] [Related]
37. Vasoactive intestinal peptide axis is dysfunctional in patients with Graves' disease.
Carrión M; Ramos-Leví AM; Seoane IV; Martínez-Hernández R; Serrano-Somavilla A; Castro D; Juarranz Y; González-Álvaro I; Gomariz RP; Marazuela M
Sci Rep; 2020 Aug; 10(1):13018. PubMed ID: 32747757
[TBL] [Abstract][Full Text] [Related]
38. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
39. Synaptic scaffolding molecule binds to and regulates vasoactive intestinal polypeptide type-1 receptor in epithelial cells.
Gee HY; Kim YW; Jo MJ; Namkung W; Kim JY; Park HW; Kim KS; Kim H; Baba A; Yang J; Kim E; Kim KH; Lee MG
Gastroenterology; 2009 Aug; 137(2):607-17, 617.e1-4. PubMed ID: 19642226
[TBL] [Abstract][Full Text] [Related]
40. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors.
Cunha-Reis D; Ribeiro JA; Sebastião AM
Brain Res; 2005 Jul; 1049(1):52-60. PubMed ID: 15935995
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
